Abstract: An information processing apparatus configured to determine a tour schedule around a facility, the information processing apparatus includes a controller configured to determine a tour time at a tour spot in the tour schedule, based on biological information on a user who is observing a process performed by equipment at the tour spot in the facility.

Abstract: The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.

Abstract: The present invention refers to a unit for viewing the time-dependent fluid flow restart, comprising two hydraulically connected reservoir tanks (1, 2); two auxiliary pipes (3); a main pipe (4) between the reservoir tanks (1, 2) and between the auxiliary pipes (3); a viewing box (15); a pressurization system (20); data acquisition software; and a particle image velocimetry (PIV) system (8); wherein the main pipe (4) is made of a transparent acrylic material that allows the viewing of the fluid inside the same; wherein the viewing box (15) encompasses the main pipe (4) and allows its viewing; and wherein the unit views the restart of the time-dependent fluid flow in transient regime.

Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.

Abstract: A charging control device of a vehicle-mountable control system includes: a plurality of chargers corresponding to respective power feeding methods; a charging communication device configured to communicate with a charging facility external to a vehicle; and an integrated controller configured to communicate with each of the plurality of chargers and the charging communication device. The electric power of the charging facility is supplied to a vehicle-mounted battery through the charger corresponding to the power feeding method of the charging facility. The plurality of chargers, the charging communication device and the integrated controller are connected to one another through a first communication line used only for charging control. Of the plurality of chargers, the charging communication device and the integrated controller, only the integrated controller is connected to a second communication line to which a traveling controller is connected.

Abstract: The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbemazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, manta or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.

Abstract: A power supply circuit includes a power supply switch configured to perform switching between connection and disconnection of an electric power supply path from a power supply to a second controller. The power supply switch is configured to be controlled by a first power supply signal transmitted from a first controller to the power supply circuit. The power supply circuit is configured to bring the power supply switch into a disconnected state to thereby bring the second controller into a stop state, when a prescribed disconnection condition is satisfied, the prescribed disconnection condition including a condition that the first power supply signal is switched from an on signal to an off signal. The second controller is configured to voluntarily enter the stop state or a power saving mode, when the second controller does not enter the stop state even if the disconnection condition is satisfied.

Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

Abstract: The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.

Abstract: A power supply circuit includes a power supply switch configured to perform switching between connection and disconnection of an electric power supply path from a power supply to a second controller. The power supply switch is configured to be controlled by a first power supply signal transmitted from a first controller to the power supply circuit. The power supply circuit is configured to bring the power supply switch into a disconnected state to thereby bring the second controller into a stop state, when a prescribed disconnection condition is satisfied, the prescribed disconnection condition including a condition that the first power supply signal is switched from an on signal to an off signal. The second controller is configured to voluntarily enter the stop state or a power saving mode, when the second controller does not enter the stop state even if the disconnection condition is satisfied.

Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

Abstract: A charging control device of a vehicle-mountable control system includes: a plurality of chargers corresponding to respective power feeding methods; a charging communication device configured to communicate with a charging facility external to a vehicle; and an integrated controller configured to communicate with each of the plurality of chargers and the charging communication device. The electric power of the charging facility is supplied to a vehicle-mounted battery through the charger corresponding to the power feeding method of the charging facility. The plurality of chargers, the charging communication device and the integrated controller are connected to one another through a first communication line used only for charging control. Of the plurality of chargers, the charging communication device and the integrated controller, only the integrated controller is connected to a second communication line to which a traveling controller is connected.

Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents.

Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophea-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.

Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.